GlassScriptPhysician profile
Isabela Miradici
NPI 1851059547
$5,320.56
in general payments reported to CMS, 2019-2025
31 companies · $1,525 in 2025
The $1,525 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $760 · 2023: $1,336 · 2024: $1,699 · 2025: $1,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,692 · Travel and Lodging: $797 · Education: $71.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,691.61 |
| Travel and Lodging | $796.57 |
| Education | $71.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,344.61 | 2023-2025 | Inspire |
| Abbott Laboratories | $970.24 | 2022-2024 | Freestyle Libre 3 |
| Medtronic, INC. | $434.30 | 2022-2023 | Cobalt Dr Mri Surescan |
| Insmed, INC. | $276.76 | 2023-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $266.84 | 2023-2025 | Tezspire, Airsupra, Breztri |
| Novo Nordisk INC | $247.41 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Electromed, INC. | $224.77 | 2024-2025 | Smartvest |
| Amgen INC. | $158.93 | 2023-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $152.09 | 2025 | Dupixent |
| United Therapeutics Corporation | $145.98 | 2023-2024 | Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $122.64 | 2024-2025 | Glassia |
| Lilly USA, LLC | $109.85 | 2022-2025 | Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.80 | 2024 | Ofev |
| Glaxosmithkline, LLC. | $107.77 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Dexcom, INC. | $104.57 | 2022-2023 | Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amryt Pharma Holdings LTD | $98.23 | 2022 | |
| Mylan Specialty L.P. | $62.71 | 2024 | Yupelri |
| Grifols USA, LLC | $46.02 | 2025 | Prolastin-C Liquid |
| Inogen, INC. | $41.27 | 2025 | |
| Viatris Specialty LLC | $38.08 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $31.36 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $31.20 | 2024 | Uptravi, Opsumit |
| Verona Pharma, INC. | $28.17 | 2025 | Ohtuvayre |
| Baxter Healthcare | $24.63 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Zoll Respicardia, INC. | $24.45 | 2025 | Remede System |
| Recordati_rare_diseases_inc. | $23.38 | 2023 | Isturisa |
| Genzyme Corporation | $22.55 | 2025 | |
| Harmony Biosciences LLC | $22.43 | 2025 | |
| Alexion Pharmaceuticals, INC. | $18.33 | 2022 | |
| Philips North America LLC | $17.36 | 2024 | (Ak6) Vest Therapy |
| Pulmonx Corporation | $13.83 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabela Miradici listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.